140 related articles for article (PubMed ID: 15050003)
1. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.
So AI; Bowden M; Gleave M
BJU Int; 2004 Apr; 93(6):845-50. PubMed ID: 15050003
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.
Gleave ME; Sato N; Goldenberg SL; Stothers L; Bruchovsky N; Sullivan LD
J Urol; 1997 May; 157(5):1727-30. PubMed ID: 9112514
[TBL] [Abstract][Full Text] [Related]
3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
4. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
5. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
Miyake H; Tolcher A; Gleave ME
Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
[TBL] [Abstract][Full Text] [Related]
6. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
8. The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer.
Zhang Z; Xu Q; Huang X; Yang J; Xu Y; Zhang G
Int J Clin Exp Pathol; 2015; 8(9):10283-93. PubMed ID: 26617736
[TBL] [Abstract][Full Text] [Related]
9. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
11. Effect of adjuvant endocrine and adjuvant chemoendocrine therapies on metastasis of androgen-dependent Shionogi carcinoma 115.
Yoshikawa T; Kitamura Y; Uchida N; Yamaguchi K; Matsumoto K
Cancer Res; 1983 Oct; 43(10):4525-9. PubMed ID: 6883315
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
[TBL] [Abstract][Full Text] [Related]
13. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
14. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Johnson MA; Iversen P; Schwier P; Corn AL; Sandusky G; Graff J; Neubauer BL
Prostate; 2005 Mar; 62(4):322-38. PubMed ID: 15389779
[TBL] [Abstract][Full Text] [Related]
15. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
Landström M; Damber JE; Bergh A
Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
[TBL] [Abstract][Full Text] [Related]
16. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
Tang Y; Wang L; Goloubeva O; Khan MA; Zhang B; Hussain A
Clin Cancer Res; 2008 May; 14(10):2936-43. PubMed ID: 18483360
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
18. Androgen suppressed apoptosis is modified in p53 deficient mice.
Colombel M; Radvanyi F; Blanche M; Abbou C; Buttyan R; Donehower LA; Chopin D; Thiery JP
Oncogene; 1995 Apr; 10(7):1269-74. PubMed ID: 7731676
[TBL] [Abstract][Full Text] [Related]
19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
20. Changes in the androgen levels in the ventral prostate of spontaneously hypertensive rats after castration.
Hu M; Xin D; Chen J; Sun G; Wang Y; Na Y
BJU Int; 2009 Aug; 104(3):406-11. PubMed ID: 19239443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
